Cardiovascular-Kidney-Metabolic syndrome pathophysiology
Insulin resistance is commonly observed in large chronic kidney disease (CKD) cohorts because CKD is tightly integrated with metabolic dysfunction in the cardiovascular-kidney-metabolic (CKM) framework. [1,2] Within CKM syndrome, insulin resistance is described as a central pathophysiologic mechanism linking metabolic disease with CKD-related adverse outcomes. [2,1]
Shared upstream drivers promoting insulin resistance in CKD
CKD is repeatedly observed alongside metabolic risk factors in population studies framed by CKM health, which supports insulin resistance as an expected co-occurrence rather than an isolated abnormality. [1] CKM health reflects interplay among metabolic risk factors, CKD, and cardiovascular physiology, which increases the likelihood that insulin resistance will be measurable in CKD cohorts. [1]
Kidney-related metabolic derangements that track with insulin resistance
Epidemiologic and mechanistic synthesis linking prediabetes and early CKD identifies insulin resistance among proposed pathways connecting impaired glucose regulation with early kidney changes and progression risk. [3] This association pattern supports insulin resistance as a frequent measurable abnormality in CKD populations, particularly when prediabetes or insulin-resistant states coexist. [3]
Inflammation and vascular dysfunction coupling CKD and insulin resistance
Low-grade inflammatory and endothelial dysfunction processes are proposed contributors to the CKD–metabolic connection that includes insulin resistance, providing a biologic rationale for the frequent finding of insulin resistance in CKD cohorts. [3] These interrelated processes align with the CKM concept that metabolic dysfunction and CKD evolve together through shared biology. [1,3]
Population evidence supporting insulin resistance as a CKD co-phenotype
In prospective CKM-stage cohorts, insulin resistance surrogate indices are associated with incident cardiovascular disease, reinforcing insulin resistance as a relevant metabolic signature within CKD–metabolic–cardiovascular stages. [2] Observational cohort evidence in prediabetes–CKD reviews further supports insulin resistance as a mechanistic contributor to early kidney involvement. [3]
Clinical implication of insulin resistance prevalence in CKD cohorts
The frequent detection of insulin resistance in CKD cohorts is consistent with CKM syndrome staging concepts, where insulin-resistant metabolic dysfunction is expected to cluster with CKD severity and downstream cardiovascular risk. [1,2]
Clinical implication for interpretation of laboratory findings
Insulin resistance findings in CKD cohorts should be interpreted as part of a broader CKM metabolic phenotype rather than as a single isolated abnormality, given the documented CKM interdependence among metabolic risk, CKD, and cardiovascular outcomes. [1]
Evidence limits
The cited evidence supports a central mechanistic role and consistent association at the level of CKM framework and observational/biologic synthesis. [1-3] Direct proof that insulin resistance is the sole cause of CKD or that it always precedes CKD is not established by the cited sources. [1-3]